368 related articles for article (PubMed ID: 13679630)
1. Recombinant antibodies for the diagnosis and treatment of cancer.
Krauss J
Mol Biotechnol; 2003 Sep; 25(1):1-17. PubMed ID: 13679630
[TBL] [Abstract][Full Text] [Related]
2. Antibodies and their fragments as anti-cancer agents.
Schaedel O; Reiter Y
Curr Pharm Des; 2006; 12(3):363-78. PubMed ID: 16454750
[TBL] [Abstract][Full Text] [Related]
3. Improving the efficacy of antibody-based cancer therapies.
Carter P
Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
[TBL] [Abstract][Full Text] [Related]
4. Generation of antibody molecules through antibody engineering.
Kipriyanov SM
Methods Mol Biol; 2003; 207():3-25. PubMed ID: 12412465
[No Abstract] [Full Text] [Related]
5. Therapeutic antibodies and antibody fusion proteins.
Rohrbach P; Broders O; Toleikis L; Dübel S
Biotechnol Genet Eng Rev; 2003; 20():137-63. PubMed ID: 14997850
[No Abstract] [Full Text] [Related]
6. Bispecific antibodies for cancer therapy.
Hollander N
Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
[TBL] [Abstract][Full Text] [Related]
7. [Phage-display technology and its application to experimental oncological therapy].
Borysowski J; Górski A
Postepy Hig Med Dosw (Online); 2004 Mar; 58():100-7. PubMed ID: 15077062
[TBL] [Abstract][Full Text] [Related]
8. Recombinant antibodies: from the laboratory to the clinic.
Albrecht H; DeNardo SJ
Cancer Biother Radiopharm; 2006 Aug; 21(4):285-304. PubMed ID: 16999595
[TBL] [Abstract][Full Text] [Related]
9. Engineering antibodies for cancer therapy.
Boder ET; Jiang W
Annu Rev Chem Biomol Eng; 2011; 2():53-75. PubMed ID: 22432610
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy.
Goshorn S; Sanderson J; Axworthy D; Lin Y; Hylarides M; Schultz J
Cancer Biother Radiopharm; 2001 Apr; 16(2):109-23. PubMed ID: 11385958
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
12. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.
Deyev SM; Lebedenko EN
Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269
[TBL] [Abstract][Full Text] [Related]
13. Recombinant antibodies: a novel approach to cancer diagnosis and therapy.
Hudson PJ
Expert Opin Investig Drugs; 2000 Jun; 9(6):1231-42. PubMed ID: 11060739
[TBL] [Abstract][Full Text] [Related]
14. A revival of bispecific antibodies.
Kufer P; Lutterbüse R; Baeuerle PA
Trends Biotechnol; 2004 May; 22(5):238-44. PubMed ID: 15109810
[No Abstract] [Full Text] [Related]
15. Numerical selection of optimal tumor imaging agents with application to engineered antibodies.
Williams LE; Wu AM; Yazaki PJ; Liu A; Raubitschek AA; Shively JE; Wong JY
Cancer Biother Radiopharm; 2001 Feb; 16(1):25-35. PubMed ID: 11279795
[TBL] [Abstract][Full Text] [Related]
16. Technology evaluation: ING-1, XOMA.
Lewis LD
Curr Opin Mol Ther; 2003 Aug; 5(4):433-6. PubMed ID: 14513688
[TBL] [Abstract][Full Text] [Related]
17. Exosome Display technology: applications to the development of new diagnostics and therapeutics.
Delcayre A; Estelles A; Sperinde J; Roulon T; Paz P; Aguilar B; Villanueva J; Khine S; Le Pecq JB
Blood Cells Mol Dis; 2005; 35(2):158-68. PubMed ID: 16087368
[TBL] [Abstract][Full Text] [Related]
18. Engineering antibodies for therapy.
Adair JR
Immunol Rev; 1992 Dec; 130():5-40. PubMed ID: 1286872
[TBL] [Abstract][Full Text] [Related]
19. Antibody engineering and its applications in tumor targeting and intracellular immunization.
Chames P; Baty D
FEMS Microbiol Lett; 2000 Aug; 189(1):1-8. PubMed ID: 10913857
[TBL] [Abstract][Full Text] [Related]
20. Antibody evolution beyond Nature.
Borrebaeck CA; Ohlin M
Nat Biotechnol; 2002 Dec; 20(12):1189-90. PubMed ID: 12454662
[No Abstract] [Full Text] [Related]
[Next] [New Search]
